RYI insider filing shows RSU dividend equivalents and vesting schedule

Rhea-AI Filing Summary

Ryerson Holding Corp (RYI) Form 4 discloses that Sundarrajan Alagu, Chief Information Officer and reporting person, received additional restricted stock units (RSUs) and accrued dividend equivalent rights on 09/18/2025. The filing shows three grants of RSUs that reflect dividend equivalents of 16.613, 32.496, and 53.758 units, which correspond to underlying common stock amounts of 2,074.819, 4,058.497, and 6,713.948 shares respectively, all with $0 price. The filing explains vesting schedules: awards from 2023 vest on 03/31/2026, 2024 awards vest on 03/31/2026 and 03/31/2027, and 2025 awards vest on 03/31/2026, 03/31/2027 and 03/31/2028. The Form 4 was signed by attorney-in-fact on 09/22/2025.

Insights

Securities Analyst

TL;DR: Routine insider equity accruals recorded for CIO; not an open-market purchase or sale.

The filing documents dividend equivalent rights credited to previously granted restricted stock units and additional RSU accruals for the Chief Information Officer on 09/18/2025. These entries reflect compensation-related equity accruals with scheduled vesting dates through 2028 and no cash purchase price, indicating administrative settlement of compensation rather than a market transaction. For investors, this is a disclosure of insider compensation and potential future dilution when the units settle into common shares.

Corporate Governance Expert

TL;DR: Disclosure aligns with typical executive equity compensation reporting; vesting timelines are specified.

The Form 4 clarifies the nature of the reported units as restricted stock units with dividend equivalent rights that vest on specified future dates. The report is consistent with Section 16 reporting requirements and includes an attorney-in-fact signature. It does not show voluntary open-market insider trading or exercised options, but it notifies stakeholders of future equity issuance tied to compensation plans.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sundarrajan Alagu

(Last) (First) (Middle)

C/O RYERSON HOLDING CORPORATION

227 W. MONROE ST., 27TH FLOOR

(Street)

CHICAGO IL 60606

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Ryerson Holding Corp [ RYI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Information Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	09/18/2025		A		16.613(2)		(3)	(3)	Common Stock	16.613	$0	2,074.819	D
Restricted Stock Units	(1)	09/18/2025		A		32.496(2)		(4)	(4)	Common Stock	32.496	$0	4,058.497	D
Restricted Stock Units	(1)	09/18/2025		A		53.758(2)		(5)	(5)	Common Stock	53.758	$0	6,713.948	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of common stock of Ryerson Holding Corporation (the "Company").

2. Represents dividend equivalent rights that accrued on the underlying award of restricted stock units. Dividend equivalent rights accrue when and as dividends are paid on the common shares underlying the applicable restricted share units and vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate.

3. The dividend equivalent rights accrued on restricted stock units that were granted on March 31, 2023 and outstanding as of September 18, 2025. These unvested restricted stock units, and the dividend equivalent rights related to such unvested restricted stock units, will vest on March 31, 2026.

4. The dividend equivalent rights accrued on restricted stock units that were granted on March 31, 2024 and outstanding as of September 18, 2025. These unvested restricted stock units, and the dividend equivalent rights related to such unvested restricted stock units, will vest on March 31, 2026 and March 31, 2027.

5. The dividend equivalent rights accrued on restricted stock units that were granted on March 31, 2025 and outstanding as of September 18, 2025. These unvested restricted stock units, and the dividend equivalent rights related to such unvested restricted stock units, will vest on March 31, 2026, March 31, 2027 and March 31, 2028.

	/s/ Camilla Rykke Merrick, attorney-in-fact	09/22/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the Ryerson (RYI) Form 4 report for Sundarrajan Alagu?

The Form 4 reports accruals and additions to restricted stock units (RSUs) and associated dividend equivalent rights for the CIO, with transactions dated 09/18/2025.

How many underlying shares are reflected by the RSU dividend equivalents?

The filing lists underlying common stock amounts of 2,074.819, 4,058.497, and 6,713.948 shares tied to the reported dividend equivalent accruals.

Do the reported transactions involve a purchase price or cash payment?

No. The entries show a $0 price and represent dividend equivalent accruals on RSUs, not cash purchases.

When do the reported RSUs vest?

Vesting is scheduled on future dates: 03/31/2026 for 2023 grants; 03/31/2026 and 03/31/2027 for 2024 grants; and 03/31/2026, 03/31/2027 and 03/31/2028 for 2025 grants.

Who signed the Form 4?

The Form 4 was signed by Camilla Rykke Merrick, attorney-in-fact on 09/22/2025.